CLINICAL TRIALS PROFILE FOR BINOSTO
✉ Email this page to a colleague
All Clinical Trials for Binosto
| Trial ID | Title | Status | Sponsor | Phase | Start Date | Summary |
|---|---|---|---|---|---|---|
| NCT02781805 ↗ | Pilot Study of Bisphosphonates for Breast Cancer | Terminated | National Cancer Institute (NCI) | Phase 1 | 2016-08-05 | The goal of this study is to mechanistically define the potential anticancer activities of the osteoporosis bisphosphonate (BP) drug alendronate, and extend the analysis to learn novel information about the impact of BP on gamma delta (γδ) T cells in breast tissues as well as epithelial breast cell differentiation of high-risk women. To this end, we have designed a BP "window trial" to examine the effect of 1 - 3 weeks administration of alendronate on women at high-risk for breast cancer, at the level of immunosurveillance and mammary epithelial cell differentiation. |
| NCT02781805 ↗ | Pilot Study of Bisphosphonates for Breast Cancer | Terminated | Wisconsin Partnership Program | Phase 1 | 2016-08-05 | The goal of this study is to mechanistically define the potential anticancer activities of the osteoporosis bisphosphonate (BP) drug alendronate, and extend the analysis to learn novel information about the impact of BP on gamma delta (γδ) T cells in breast tissues as well as epithelial breast cell differentiation of high-risk women. To this end, we have designed a BP "window trial" to examine the effect of 1 - 3 weeks administration of alendronate on women at high-risk for breast cancer, at the level of immunosurveillance and mammary epithelial cell differentiation. |
| NCT02781805 ↗ | Pilot Study of Bisphosphonates for Breast Cancer | Terminated | University of Wisconsin, Madison | Phase 1 | 2016-08-05 | The goal of this study is to mechanistically define the potential anticancer activities of the osteoporosis bisphosphonate (BP) drug alendronate, and extend the analysis to learn novel information about the impact of BP on gamma delta (γδ) T cells in breast tissues as well as epithelial breast cell differentiation of high-risk women. To this end, we have designed a BP "window trial" to examine the effect of 1 - 3 weeks administration of alendronate on women at high-risk for breast cancer, at the level of immunosurveillance and mammary epithelial cell differentiation. |
| NCT04403698 ↗ | The Use of Steovess/Binosto After Denosumab Discontinuation to Prevent Increase in Bone Turnover | Recruiting | Amgen | Phase 2 | 2019-11-13 | It is hypothesized that effervescent alendronate will be able to maintain bone turnover markers within the pre-menopausal reference range and thereby reducing the likelihood of bone turnover associated changes (rebound effect), after discontinuation of denosumab treatment in a non-osteoporotic population. |
| NCT04403698 ↗ | The Use of Steovess/Binosto After Denosumab Discontinuation to Prevent Increase in Bone Turnover | Recruiting | EffRx Pharmaceuticals | Phase 2 | 2019-11-13 | It is hypothesized that effervescent alendronate will be able to maintain bone turnover markers within the pre-menopausal reference range and thereby reducing the likelihood of bone turnover associated changes (rebound effect), after discontinuation of denosumab treatment in a non-osteoporotic population. |
| NCT04403698 ↗ | The Use of Steovess/Binosto After Denosumab Discontinuation to Prevent Increase in Bone Turnover | Recruiting | University Hospital, Ghent | Phase 2 | 2019-11-13 | It is hypothesized that effervescent alendronate will be able to maintain bone turnover markers within the pre-menopausal reference range and thereby reducing the likelihood of bone turnover associated changes (rebound effect), after discontinuation of denosumab treatment in a non-osteoporotic population. |
| >Trial ID | >Title | >Status | >Sponsor | >Phase | >Start Date | >Summary |
Clinical Trial Conditions for Binosto
Condition Name
Clinical Trial Locations for Binosto
Trials by Country
Clinical Trial Progress for Binosto
Clinical Trial Phase
Clinical Trial Sponsors for Binosto
Sponsor Name
